Canaccord Adams downgrades ResMed (NYSE: RMD) from Buy to Hold. Price target $48.
Analyst Jason Mills�said, " While we remain ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE